Spots Global Cancer Trial Database for deferasirox
Every month we try and update this database with for deferasirox cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. | NCT02663752 | Myelodysplastic... | Bone marrow asp... Deferasirox | 18 Years - | Novartis | |
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | NCT01892644 | Hemochromatosis Myelodysplastic... | Deferasirox Venesection Deferasirox | 18 Years - 80 Years | Haukeland University Hospital | |
| Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study | NCT01326845 | Myelodysplastic... Transfusional I... | Deferasirox | 18 Years - | Novartis | |
| Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients | NCT00117507 | Myelodysplastic... Iron Overload | Deferasirox | 18 Years - | Novartis | |
| This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. | NCT01250951 | Myelodysplastic... Thalassemia | Deferasirox | 2 Years - | Novartis | |
| Safety, Tolerability, and Efficacy of Deferasirox in MDS | NCT00469560 | Myelodysplastic... Hemosiderosis | Deferasirox | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment | NCT01370980 | Cancer | 18 Years - | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | ||
| Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents | NCT03387475 | Myelodysplasia | Deferasirox | 18 Years - 100 Years | University Hospital, Grenoble | |
| The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | NCT02413021 | Acute Myeloid L... Acute Lymphoid ... | Cytarabine Deferasirox | 15 Years - | Isfahan University of Medical Sciences | |
| Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment | NCT01370980 | Cancer | 18 Years - | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | ||
| Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study | NCT00940602 | Myelodysplastic... | Deferasirox Placebo | 18 Years - | Novartis | |
| Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. | NCT01868477 | Low and Int 1-r... | Deferasirox DFX... Erythropoietin ... Deferasirox DFX... | 18 Years - | Novartis | |
| Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment | NCT01370980 | Cancer | 18 Years - | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | ||
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | NCT01892644 | Hemochromatosis Myelodysplastic... | Deferasirox Venesection Deferasirox | 18 Years - 80 Years | Haukeland University Hospital | |
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | NCT01892644 | Hemochromatosis Myelodysplastic... | Deferasirox Venesection Deferasirox | 18 Years - 80 Years | Haukeland University Hospital | |
| Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome | NCT02943668 | Anemia Myelodysplastic... | Deferasirox Laboratory Biom... | 18 Years - | Fred Hutchinson Cancer Center | |
| Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | NCT00602446 | Breast Cancer Iron Overload Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Neuroblastoma Ovarian Cancer | deferasirox | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
